V. Popat

发表

P854 Construction of the immune landscape of durable response to checkpoint blockade therapy by integrating publicly available datasets

Daniel K. Wells, V. Thorsson, Y. Najjar, 2020, Journal of Immunotherapy for Cancer.

Clinical value of event-free survival in acute myeloid leukemia.

M. Konopleva, M. Andreeff, H. Kantarjian, 2020, Blood advances.

Association between Antibiotic Exposure and Systemic Immune Parameters in Cancer Patients Receiving Checkpoint Inhibitor Therapy

D. Gerber, Quanzhen Li, E. Wakeland, 2022, Cancers.

Lack of Association Between Radiographic Tumor Burden and Efficacy of Immune Checkpoint Inhibitors in Advanced Lung Cancer.

Jason Y. Park, Yang Xie, D. Gerber, 2020, The oncologist.

Association between body mass index, dosing strategy, and efficacy of immune checkpoint inhibitors

Jason Y. Park, Yang Xie, D. Gerber, 2021, Journal for ImmunoTherapy of Cancer.

DC-HIL/Gpnmb Is a Negative Regulator of Tumor Response to Immune Checkpoint Inhibitors

D. Gerber, K. Ariizumi, P. Cruz, 2019, Clinical Cancer Research.

75 Generalizability of potential biomarkers of response to CTLA-4 and PD-1 blockade therapy in cancer

Daniel K. Wells, Dante S. Bortone, V. Thorsson, 2020 .

Hyperprogressive disease: a distinct effect of immunotherapy?

D. Gerber, V. Popat, 2019, Journal of thoracic disease.

Statin Intolerance, anti-HMGCR Antibodies, and Immune Checkpoint Inhibitor-Associated Myositis: A "Two-Hit" Autoimmune Toxicity or Clinical Predisposition?

Jason Y. Park, Yang Xie, D. Gerber, 2020, The oncologist.

Highly variable timing renders immunotherapy efficacy and toxicity impractical biomarkers of one another in clinical practice.

H. Hammers, F. Fattah, D. Hsiehchen, 2024, Frontiers in immunology.